NCT05831878View on ClinicalTrials.gov

RC48-ADC in HER2-low Advanced Breast Cancer

NARecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

August 31, 2026

Conditions

Advanced Breast Cancer

Interventions

DRUG

Disitamab vedotin

2.0mg/kg, iv, day1, every 2 weeks

Trial Locations (1)

200127

RECRUITING

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors

lead

RenJi Hospital

OTHER